Feedback
Settings

Settings

Goto Application

562 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/76 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 57
1.20210246431Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus Receptor
US - 12.08.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No 17027295 Applicant Erasmus University Medical Center Rotterdam Inventor Bartholomeus Leonardus Haagmans

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

2.WO/2021/209275PARTICLES, DNA & RNA
WO - 21.10.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/EP2021/058821 Applicant NOVOSCOPE IP LIMITED Inventor CLUBE, Jasper
The invention provides competitive particles, such as virus-like particles, RNAs and DNAs for the treatment or prevention of viral infections and methods of using such particles for treating or preventing or reducing the risk of viral infections (or symptoms thereof) in a subject, such as a human or animal subject. For example, the method herein is a method of reducing or reducing the establishment of a zoonotic population of a virus in an animal, such as a livestock or wild animal (eg, a bat, camelid or a Pholidota (eg, a pangolin)).
3.WO/2022/135683USE OF A BIRNAVIRUS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF A DISEASE CAUSED BY A NIDOVIRUS
WO - 30.06.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/EP2020/087550 Applicant PROBIOGEN AG Inventor KOVESDI, Imre
The present invention relates to a birnavirus for use in the treatment of a disease caused by a nidovirus. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment of a disease caused by a nidovirus. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment of a disease caused by a nidovirus.
4.WO/2021/178416IMMUNE-MEDIATED CORONAVIRUS TREATMENTS
WO - 10.09.2021
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
 Appl.No PCT/US2021/020490 Applicant HEAT BIOLOGICS, INC. Inventor HUTCHINS, Jeff T.
The present invention provides an expression vector, host cells, methods and kits for the treatment or prevention of a coronavirus infection in a subject.
5.WO/2022/175436INFLUENZA VIRUS DEFECTIVE INTERFERING PARTICLES FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF CORONAVIRIDAE INFECTION
WO - 25.08.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
 Appl.No PCT/EP2022/054047 Applicant MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. Inventor KUPKE, Sascha
The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.
6.WO/2021/216467A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES
WO - 28.10.2021
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
 Appl.No PCT/US2021/028004 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor NEL, Andre, E.
In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against one or more viral proteins and/or protein fragments. In certain embodiments the immunogenic nanoparticles raise an immune response directed against a virus (e.g., SARS-CoV-2 (2019-nCoV), SARS-CoV-2, and MERS-CoV, and the like). In certain embodiments the immunogenic nanoparticles comprise a nanoparticle formed from one or more biocompatible polymer(s), one or more viral proteins or fragments thereof encapsulated within or attached to the biocompatible polymer(s) where the viral protein or fragment thereof comprises an antigen to which an immune response is to be induced by administration of the immunogenic nanoparticle to a mammal and where the immunogenic nanoparticle further comprises an adjuvant (e.g., a STING agonist).
7.WO/2022/164937TREATMENT OF CANCER USING MRNA-MEDIATED VIRUS VACCINATION ANTIGENS DELIVERED BY ATTENUATED BACTERIA
WO - 04.08.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/US2022/013949 Applicant BRADLEY, Christopher Inventor BRADLEY, Christopher
Disclosed are methods of treating tumors in a subject including but not limited to reducing the size of a primary tumor, preventing progression of a tumor to metastasis, and reducing the extent of metastasis; comprising administering to the subject an attenuated bacteria that expresses an mRNA-mediated virus vaccination antigen in an amount effective to treat the tumor. Further disclosed are methods of preventing infection of cells in a subject by a virus and/or preventing or reducing in the subject symptoms of a disease caused by the virus; comprising administering to the subject an attenuated bacteria that expresses an mRNA-mediated virus vaccination antigen in an amount effective to protect the subject against the virus and/or its effects. Further disclosed are pharmaceutical compositions, cancer immunotherapy compounds, virus vaccines and therapeutic cancer vaccines comprising an attenuated bacteria that expresses an mRNA-mediated virus vaccination antigen, and methods of developing the same.
8.WO/2022/118226MULTICISTRONIC RNA VACCINES AND USES THEREOF
WO - 09.06.2022
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
 Appl.No PCT/IB2021/061203 Applicant SEQIRUS INC. Inventor ALLEN, Pirada
The present disclosure relates to multicistronic RNA vaccines and uses thereof. The present disclosure also relates to multicistronic conventional mRNA vaccines and uses thereof. The present disclosure further relates to multicistronic self-replicating RNA vaccines and uses thereof.
9.20220193206METHODS AND COMPOSITIONS FOR TREATING CORONAVIRUS INFECTIONS
US - 23.06.2022
Int.Class A61K 38/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
47acting on glycosyl compounds (3.2), e.g. cellulases, lactases
 Appl.No 17585022 Applicant Morehouse School of Medicine Inventor Michael POWELL

The present application relates to a compositions and methods comprising or expressing a HEVAR or MOMO30 protein derived from Momordica balsamina. The HEVAR or MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for treating or preventing viral infections, particularly those caused by coronaviruses, such as SARS-CoV-2.

10.20220054601Methods and compositions for treating coronavirus infections
US - 24.02.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 17342897 Applicant MOREHOUSE SCHOOL OF MEDICINE Inventor Michael Powell

The present application relates to a compositions and methods comprising or expressing a HEVAR or MOMO30 protein derived from Momordica balsamina. The HEVAR or MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for treating or preventing viral infections, particularly those caused by coronaviruses, such as SARS-CoV-2.

# -